Core Viewpoint - The Shandong Provincial Government is implementing a comprehensive reform plan to enhance the regulation of pharmaceuticals and medical devices, aiming to promote high-quality development in the pharmaceutical industry, which is crucial for national economy and security [1][2]. Group 1: Policy Initiatives - The Shandong Provincial Health Commission will utilize a combination of policy guidance, service optimization, and regulatory assurance to inject new momentum into the high-quality development of the pharmaceutical industry [1]. - A dynamic linkage mechanism will be established between hospital drug supply and the medical insurance drug catalog, facilitating the clinical application of innovative drugs [1]. Group 2: Clinical Evaluation and Support - A comprehensive clinical evaluation system will be developed to assess the safety, efficacy, economic viability, innovation, suitability, and accessibility of drugs, particularly focusing on conditionally approved innovative drugs [2]. - Clinical trial support capabilities will be enhanced by incorporating clinical research into the evaluation of public hospitals' quality, allowing for dedicated beds for innovative drug trials not to count towards total bed numbers [2]. Group 3: Traditional Medicine and Collaboration - The "Qilu Traditional Chinese Medicine Brand Project" will be implemented to promote the quality and added value of traditional Chinese medicine, including the establishment of ecological planting bases for medicinal materials [2]. - A regular consultation mechanism will be established among the Health Commission, Medical Insurance Bureau, and Drug Administration to facilitate data sharing and address cross-sector issues related to innovative drug evaluation and clinical application [3].

Core Viewpoint - The State Council's meeting on December 31 approved the revised draft of the Drug Administration Law Implementation Regulations, emphasizing the importance of timely updates to drug management laws for ensuring public safety and promoting the healthy development of the pharmaceutical industry [1] Group 1: Drug Safety and Regulation - The revised regulations stress comprehensive supervision throughout the entire drug lifecycle, from research and development to usage, directly safeguarding public medication safety [1] - The meeting highlighted the need for stringent quality supervision across the entire drug supply chain and a strong crackdown on illegal activities in the pharmaceutical sector [1] Group 2: Industry Development - The regulations aim to enhance the drug research and registration system, accelerating the review and approval of breakthrough therapies, which can invigorate innovation within the industry [1] - By improving the review system and expediting the approval of innovative drugs, the regulations encourage pharmaceutical companies to invest in research and development, facilitating a shift from generic to innovative drug production [1] Group 3: Legal Framework - The revisions are intended to solidify the legal foundation for drug regulation, ensuring that stringent regulatory requirements are codified into law, thus providing a clear legal basis for enforcement [1]

Group 1 - The "2025 Responsibility Shine Qilu" annual event recognized Qilu Pharmaceutical as a "Responsible Enterprise" for its outstanding performance in drug research and development, public health support, and industry responsibility [1] - The event was attended by leaders from the Shandong Provincial Health Commission, Shandong Digital Culture Group, and representatives from nearly a hundred medical institutions, highlighting the importance of recognizing contributions to the health sector in Shandong [1] - The awards were based on public recommendations, sentiment analysis, big data evaluation, and reader feedback, aiming to set benchmarks for industry responsibility [1] Group 2 - Qilu Pharmaceutical focuses on major diseases such as tumors, infections, and autoimmune diseases, increasing R&D investment and establishing a global innovation platform to ensure high-quality drug supply [2] - The company has implemented a comprehensive quality control system and adheres to international standards to ensure the safety and reliability of its products [2] - Qilu Pharmaceutical actively engages in social responsibility through initiatives like "Healthy China, Qilu Together," providing free health screenings and educational outreach in underserved areas [2] Group 3 - In 2025, Qilu Pharmaceutical achieved significant breakthroughs, including multiple innovative drugs entering critical clinical trial phases and establishing a leading smart pharmaceutical production base [3] - The company has enhanced production efficiency and quality control through digital and intelligent transformations, ensuring stable drug supply [3] - Qilu Pharmaceutical aims to continue its commitment to pharmaceutical innovation and public health services, responding to national health initiatives and driving high-quality development in the Chinese pharmaceutical industry [3]

Core Insights - The Hong Kong pharmaceutical market is becoming a key area for investing in future pharmaceutical trends due to its unique asset structure and industry representation [1][2] - The Southern Fund's QDII fund aims to provide investors with a high-quality tool for participating in Hong Kong pharmaceutical investments, leveraging deep insights into industry trends and active management capabilities [1][2] Market Structure - Approximately 70% of the Hong Kong pharmaceutical market consists of innovative assets, including innovative drugs and devices, while about 20% is made up of emerging medical forms such as new consumer healthcare and AI medical applications [2][3] - The market's structure positions it as a concentrated representation of new productive forces in the pharmaceutical industry, highlighting the global breakthroughs in the innovative drug industry and the rise of new consumer healthcare [2][3] Innovation as a Core Driver - The innovative drug industry chain is identified as the core asset of the Hong Kong pharmaceutical market, with long-term value derived from multiple industry dividends [3] - China's recognized capabilities in innovative drug research and development, combined with domestic healthcare payment support and access to a trillion-dollar global market, create a broad stage for commercialization [3] Fund Strategy - The Southern Fund's QDII fund aims to balance risk and return, allowing investors to participate comfortably in Hong Kong pharmaceutical investments [4][5] - During volatile periods, the fund employs strict risk control measures to minimize drawdowns, while in bullish trends, it seeks to fully capture the elastic returns of the market [4][5] Investment Approach - The fund manager emphasizes the importance of a strategic approach to investing in the pharmaceutical sector, advocating for a method that allows for accumulation during downturns and participation during upswings [5][6] - The fund's strategy includes active management to capture opportunities in innovative drugs, CXO, and new consumer healthcare sectors while avoiding the risks associated with concentrated strategies [5][6] Active Management and Experience - The fund's excess returns are derived from a systematic investment framework that includes profit-taking strategies and identifying undervalued quality stocks [6] - This diversified approach aims to capture the core trends of the Hong Kong pharmaceutical market while reducing volatility and enhancing the overall investment experience [6][7]